Clinical Trial Detail

NCT ID NCT03213041
Title Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Northwestern University
Indications

triple-receptor negative breast cancer

Therapies

Carboplatin + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.